Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.53 |
| ▸ | FAAH | O00519 | 8/20 | 0.53 |
| ▸ | CNR1 | P21554 | 2/20 | 0.53 |
| ▸ | CASR | P41180 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13766918 | 0.90 | CNR2 (0.63) | CNR2FAAHCNR1CASRPOLB | |
| SCHEMBL12576479 | 0.83 | EPHX2 (0.52) | CNR2CNR1EPHX2HTT | |
| SCHEMBL13766703 | 0.82 | POLB (0.52) | CNR2FAAHCNR1CASRPOLB | |
| SCHEMBL20108738 | 0.81 | CNR1 (0.40) | CNR2CNR1NPC1RAB9AEPHX2 | |
| SCHEMBL14098589 | 0.79 | CNR2 (0.50) | CNR2FAAHCNR1CASRPOLB | |
| SCHEMBL8122848 | 0.79 | CNR2 (0.52) | CNR2FAAHCNR1MEN1KMT2A | |
| SCHEMBL13766922 | 0.78 | EPHX2 (0.54) | CNR2CNR1EPHX2HTT | |
| SCHEMBL13766923 | 0.77 | EPHX2 (0.51) | CNR2CNR1EPHX2HTT | |
| SCHEMBL13766740 | 0.77 | CNR2 (0.54) | CNR2FAAHCNR1CASREPHX2 | |
| SCHEMBL1407002 | 0.77 | EPHX1 (0.52) | CNR2FAAHCNR1CASRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-8871208-B2 | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof | ABBVIE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | CNR2 1324/4885FAAH 1998/4885CNR1 970/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | CNR2 1215/4885FAAH 3010/4885CNR1 965/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | CNR2 2776/4885FAAH 264/4885CNR1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.